Breaking news
Quantum-Si Inks Deal to Distribute Platinum Protein Sequencing Instrument in Japan
Under the agreement, Tomy Digital Biology will be the first company to sell the instrument and associated consumables in that country.
Cepheid Gains Expanded FDA Clearance With CLIA Waiver for Multiplex Vaginal Panel
The panel detects bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis within an hour from a single sample.
Black Death Plague Shows Limited Ancestry, Immune Effects in Study of Ancient Cambridge
Researchers saw limited ancestry or immune gene shifts linked to the Black Death pandemic in an analysis of 275 pre- and post-plague individuals in Cambridgeshire.
Complete Genomics, Gencove Ink Comarketing Agreement for Low-Pass Whole-Genome Sequencing
The firms will offer a bundled solution combining Gencove's data management and analytics platform with Complete Genomics' sequencing products.
Jury Awards Ravgen $57M in NIPT Patent Suit Against Natera
A federal court jury found that Natera infringed on Ravgen's patents on the methods used to identify genetic abnormalities through prenatal screening.
'All of Us' Sequencing Data Links Titin Mutations, Heart Conditions in African Ancestry Individuals
As in Europeans, a specific type of titin gene mutation increased atrial fibrillation, dilated cardiomyopathy, and heart failure risk, pointing to the potential importance of testing.
Top Five Articles on GenomeWeb Last Week: JP Morgan Healthcare Conference, NanoString Layoffs, More
Last week, GenomeWeb's readers were most interested in articles about omics and molecular diagnostics companies providing business updates at the JP Morgan Healthcare Conference.
Illumina, Ginkgo Bioworks Ink Global Comarketing Agreement for Biosecurity
The deal builds on a $70 million investment Ginkgo received in May 2020 from Illumina and other investors to build NGS-based COVID testing infrastructure.
Parse Biosciences Acquires RNA-seq Data-Analysis Firm Biomage
Privately held Biomage, based in Scotland, develops software for single-cell RNA sequencing data analysis including the cloud-based Cellenics platform.
Optithera, ELNA Medical Group, Génome Québec Partner on Saliva-Based Type 2 Diabetes Test
Optithera is developing a prognostic test to asses the risk that patients with type 2 diabetes will develop severe complications before symptoms develop.